2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1046 Natural history of smoldering multiple myeloma under standardized follow‑up and genomic risk integration: First results from the prospective carrismm study (IFM 2017-04)

Titouan Cazaubiel, MD, Anais Schavgoulidze Jr, PharmD PhD2, Cyrille Hulin, MD3, Lionel Karlin, MD4, Ronan Le Calloch, MD5, Jacques Delaunay6, Emilie Chalayer, MD, PhD7, Cyrille Touzeau Sr, MD, PhD8, Cécile Sonntag, MD9, Thomas Chalopin Jr, MD10, Driss Chaoui, MD11, Adrien Trebouet12, Frederic Maloisel, MD13, Selim Corm14, Philippe Rey, MD15, Clara Mariette, MD16, Gaspard Jadot17, Reza Tabrizi, MD18, Marion Loirat19, Pascal Lenain20, Pascal Godmer21, Jean Valere Malfuson22, Regis Kaphan23, Sophie Rigaudeau, MD24, Claire Calmettes, MD25, Laurent Frenzel26, Marie Christiane Vekemans27, Magaret Macro, MD28, Laure Vincent Jr, MD29, Hélène Demarquette, MD30, Frederique Orsini Piocelle, MD31, Xavier Leleu Sr, MD, PhD32, Laure Derrier33, Yasmina Bordin34, Caroline Moreau, PhD35, Aurore Perrot Sr, MD36, Ronan Garlantezec37, Jill Corre Sr, PharmD38, Olivier Decaux, MD PhD39
1 Hospital Center University de Bordeaux, Bordeaux, France, Research Center in Cancer de Toulouse, Toulouse, France
2 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
3 Hospital Center University de Bordeaux, Bordeaux, France
4 Centre Hospitalier University Lyon-Sud, Pierre-Bénite, France
5 Centre Hospitalier de Cornouaille, Quimper, France
6 Hôpital Privé du Confluent, Nantes, France
7 University Hospital Saint Etienne, Saint Etienne, France
8 University Hospital of Nantes, Nantes, France
9 Chu Strasbourg, Strasbourg, France
10 Centre hospitalier universitaire de Tours, Tours, France
11 CH Argenteuil, Argenteuil, France
12 Centre Hospitalier de Bretagne Sud, Lorient, France
13 Strasbourg Oncologie libérale, Strasbourg, France
14 Médipôle de Savoie, Challes-les-Eaux, France
15 Centre Léon Bérard, Lyon, France
16 CHU de Grenoble, Grenoble, France
17 CHU UCL Namur site Godinne, Yvoir, Belgium
18 Centre Hospitalier de Mont-de-Marsan, Mont-de-Marsan, France
19 CH Saint-Nazaire, Saint-Nazaire, France
20 Centre Henri Becquerel, Rouen, France
21 Centre Hospitalier Bretagne-Atlantique, Vannes, France
22 Hôpital d'Instruction des Armées Percy, Clamart, France
23 Centre Hospitalier de Cannes, Cannes, France
24 Hôpital André Mignot, Le Chesnay-Rocquencourt, France
25 Centre Hospitalier de Périgueux, Périgueux, France
26 Hôpital Necker, Paris, France
27 Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
28 University Hospital Center of Caen, Caen, France
29 Hôpital Saint-Éloi, Montpellier, France
30 Centre Hospitalier de Dunkerque, Dunkerque, France
31 Centre Hospitalier Annecy Genevois, Epagny Metz-Tessy, France
32 Poitiers University Hospital, Poitiers, France
33 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
34 Intergroupe Francophone du Myélome, Paris, France
35 Chu Rennes, Rennes, France
36 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
37 Chu Rennes, Rennes, France
38 Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
39 Chu Rennes, Rennes, France

Introduction:
Smoldering multiple myeloma (SMM) is an asymptomatic precursor of multiple myeloma (MM), as defined by the IMWG in 2014. Its clinical course is highly heterogeneous. Although the 2/20/20 model stratifies progression risk, variability persists among patients, and clinical criteria alone only partially identify those at risk of early progression. This uncertainty contributes to the ongoing debate between surveillance and early intervention for high-risk SMM.
A better understanding of SMM natural history is needed, including characterization of distinct patterns of progression and evaluation of clinical and emerging prognostic factors to identify patients at highest risk of progression. To address this clinical need, we conducted CARRISMM (IFM 2017-04; NCT04144387), a multicenter, prospective observational study in a homogeneous cohort of patients with SMM.

Methods:
Eligible patients had a confirmed and recent (≤1 year) diagnosis of SMM according to IMWG 2014 criteria. The primary endpoint was progression to MM, defined by CRAB (hypercalcemia, renal insufficiency, anemia, or bone lesions) or SLiM criteria (≥60% clonal plasma cells, serum free light chain ratio ≥100, or >1 focal MRI lesions). Secondary evaluation criteria included the risk of progression based on previously described clinical and biological predictive factors, and the risk of progression based on genetic abnormalities.
Screening procedures included bone marrow analysis with genomic assessment by targeted next‑generation sequencing, computed tomography (CT), magnetic resonance imaging (MRI) and/or positron emission tomography/CT, and blood and urine analyses, with centralized assessment of serum free light chains. Longitudinal follow‑up consisted of bone marrow analysis and MRI at 12 and 24 months, blood, and urine analyses every 6 months up to 5 years.

Results:
A total of 495 screened patients were evaluated, including 107 screen failures due to evidence of MM, resulting in 388 included patients. Median age was 67 years (range 31-93). After a median follow‑up of 29.6 months, median time to progression to MM was not reached (NR) (95% CI 51.9-NR), and the 2‑year progression rate was 22%. Among progressing patients, 55% met CRAB criteria, 30% met only SLiM criteria, and 15% progressed through other manifestations including amyloidosis and plasma cell leukemia. Excluding other progression types, anemia occurred in 38 patients (37%), bone lesions in 36 (35%) including only six fractures, serum free light chain ratio ≥100 in 31 (30%), focal MRI lesions in 23 (22.5%), BMPC ≥60% in 8 (8%), renal insufficiency in 6 (6%) without stage IV disease, and hypercalcemia in 5 (5%). According to the 2/20/20 model, 112 patients (29%) were classified as low risk, 162 (43%) as intermediate risk, and 106 (28%) as high risk. The risk of progression at 2 years increased across groups, with rates of 5%, 18% (HR 2.5, 95% CI 1.3–4.95), and 43% (HR 6.8, 95% CI 3.55–13.1), respectively. Regarding patients with non‑high‑risk SMM, 13% progressed within 24 months.
We then assessed the genomic landscape of SMM at diagnosis, and evaluated the relevance of the IMS/IMWG consensus genomic staging, initially developed for MM patients. In this cohort, 36 patients (12%) were classified as high risk based on cytogenetic criteria, with a median time to progression of 24 months (95% CI 18-NR), and 261 (88%) as standard risk, with a median time to progression NR (95% CI 51-NR; p<0.05). Furthermore, the genomic landscape of early progressors (≤ 24 months) differed significantly from that of patients who did not progress within 24 months, with notably higher frequencies of t(4;14) (18% vs 5%, p<0.05) and del(1p32) (11% vs 3%, p<0.05). Integrating cytogenetic abnormalities improved the risk stratification of the 2/20/20 model and enabled the identification of SMM with ultra‑high risk of progression.

Conclusion:
Overall, this prospective and homogeneous cohort enabled a detailed description of the clinical course of patients with SMM according to the 2014 IMWG criteria. Few progressions with meaningful clinical impact were observed, reflecting the effectiveness of a standardized and regular follow‑up strategy. The 2/20/20 model provided efficient risk stratification for progression, but genomic abnormalities significantly influenced patient outcomes and further improved risk discrimination.

Titouan Cazaubiel, MD: Amgen - Honoraria; Menarini Stemline - Honoraria; Sanofi - Honoraria; GSK - Honoraria; BMS - Honoraria; Pfizer - Honoraria; Janssen - Honoraria; BMS - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Menarini Stemline - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)